We have investigated the possibility of inducing cytotoxic T lymphocytes (CTL) to Ras containing a mutation at position 61 or to normal Ras, using recombinant vaccinia viruses expressing these proteins. CTL from C57B1/10 mice immunized with vaccinia expressing mutant Ras showed specificity for the mutant Ras protein and recognition of normal Ras was inefficient. The opposite specificity was observed after immunization with vaccinia expressing normal Ras, since CTL isolated from these mice recognized normal Ras well and mutant Ras inefficiently. Levels of endogenous Ras expression were insufficient for lysis by these CTL. One CTL epitope mapped to amino acids 60-67 and residue 61 was critical for T cell recognition. CTL generated against mutant Ras protein recognized peptide 60-67 containing mutant residue 61, while anti-normal Ras CTL recognized the wild-type 60-67 sequence. A second epitope mapped to residues 152-159 of Ras and was recognized equally well by CTL raised to normal or mutant Ras. The murine data raise the possibility of exploiting Ras-specific CTL for targeted immunotherapy of certain human cancers.
T
he concept of immunotherapy of cancer rests on the activation of effector mechanisms that can specifically recognize and eliminate tumor cells. Since CTL are responsible for tumor rejection in many experimental models (1), they represent promising anticancer effectors. The limited success of reintroducing cytokine-activated lymphocytes into cancer patients might be due to the lack of specificity (2, 3) . Although it is possible to isolate CTL from tumor-infiltrating lymphocytes that specifically lyse the patients tumor cells (4) (5) (6) (7) , the antigens recognized are usually unknown, making targeted therapy a difficult task. Significant progress was made recently when the gene encoding a CTL-recognized melanoma antigen was cloned and shown to be expressed in 40% of human melanomas (8) .
Oncogenes are attractive targets for immune intervention because they are often mutated or overexpressed in cancer cells (9) . The Ras protein is implicated in a large number of human malignancies, contributing to transformation by abnormally high levels of expression (10) (11) (12) or through mutations at either position 12, 13, or 61 (13) (14) (15) . Although MHC class II-restricted Th cells have been generated to synthetic Ras peptides (16) (17) (18) (19) , it remained unclear whether these T cells can recognize cells expressing Ras endogenously. Since Ras is not a secreted or cell surface protein and not known to be present in the endo-lysosomal compartment where loading of MHC class II molecules normally occurs (20) , presentation to Th cells might be very inefficient. In contrast, the cytoplasmic location of Ras may allow ready access to the MHC class I presentation pathway (21) , which is required for CTL recognition. In this study we have tested whether peptide epitopes derived from endogenously expressed Ras are presented by class I molecules and whether they stimulate CTL responses. N-Ras with a glutamine to lysine mutation at position 61 (gifts from Alan Hall, Institute of Cancer Research, Chester Beatty, London, UK) were inserted into the vaccinia expression plasmid pSCII, and recombinant virus was generated as described (25) . Recombinant virus containing the E7 gene of human papilloma virus (Vac-E7; gift from Lionel Crawford, Department of Pathology, Cambridge University, Cambridge, UK) was used as control in CTL assays.
CTL Generation. CTL Assays. CTL activity was tested in standard 4-h StCr release assays using SlCr-labeled target cells as described (26) . Briefly, RMA or EL4 cells were SlCr labeled for 1 h at 37~ and then seeded at 5 x 103 per well in 96-well microtiter plates. Effector CTL were added to obtain indicated E/T ratios, and after a 4-h incubation at 37~ 100 out of 200/~1 medium per well was harvested and radioactivity was counted in a gamma counter (Pharmacia/LKB). Percent specific lysis was calculated using the equa- MHC Class I Binding Assay. RMA-S cells were cultured at 26~
overnight to upregulate levels of class I expression (33) . Cells were seeded in triplicates on 96-well plates (2 x 10 ~ cells/well), and Ras peptides or K b or D ~ binding control peptides were added. After incubation for I h at 37~ levels of class I expression were determined by indirect immunofluorescence staining and FACS | analysis as described (32) .
Results and Discussion
Since vaccinia virus has been shown to be efficient in inducing CTL responses (34-36), we have chosen to use this vector for stimulation of anti-Ras responses in C57B1/10 mice. DNAs encoding normal human N-Ras or mutant N-Ras containing a glutamine to lysine change at position 61 were inserted into the vaccinia genome and expressed from the earlylate 7.5 promoter. Mice were immunized and boosted twice and spleen cells were restimulated in vitro with infected stimulator cells.
CTL lines from animals immunized with Vac-Ras 6t lysed H-2b-derived R.MA cells infected with the immunizing virus more efficiently than Vac-Ras-infected cells (Fig. 1 A) , while CTL from Vac-Ras-immune mice lysed targets expressing Ras better than Ras6t-expressing cells (Fig. 1 B) . Target cells infected with a control vaccinia construct expressing the E7 protein of human papilloma virus showed only background lysis, indicating that vaccinia-encoded proteins did not stimulate detectable CTL responses. The observed Ras-specific lysis was mediated by CD8 + T cells since anti-CD8 but not anti-CD4 mAbs inhibited lysis (Fig. 1 E) . CTL lysis was not dependent upon vaccinia infection but was also seen with transfected target cells. Ras6~-specific CTL lysed EL4 cells transfected with Ras 6~ well and showed little lysis of target cells transfected with normal Ras (Fig. 1 C) . Conversely, Ras hut not Ras 6t transfectants were lysed efficiently by CTL raised against normal Ras (Fig. I D) . These CTL did not lyse untransfected EL4 cells, indicating that levels of endogenous Ras expression were insufficient for CTL recognition.
To map the epitopes recognized by Ras-specific CTL lines, we took advantage of known peptide binding motifs for the MHC class I molecules K b and D b (37) . Two K ~ but no D b motifs were present in the Ras sequence. Amino acids 60-67 contained a K b motif and we synthesized 8mer peptides P60 N and P60 ~ corresponding to the normal or mutant Ras sequence, respectively. Peptide P152, containing the second K ~ motif spanning amino acids 152-159, was also synthesized. First, binding to class I molecules was measured in a cell surface binding assay (32) using the peptide loadingdeficient cell line RMA-S. All three Ras peptides bound to K b but not D b (Fig. 2) , demonstrating the value of predictive binding motifs. CTL generated against Ras 6~ lysed target cells pulsed with P60 ~ well and showed some crossrecognition of peptide P60 N (Fig. 3 A) , while CTL raised against normal Ras recognized P60 N and showed little crossrecognition of P60 ~ (Fig. 3 B) . Both CTL recognized target cells pulsed with peptide P152 equally well (Fig. 3, C and  D) . As expected, CTL recognition of P60 and P152 was K h restricted, which was confirmed by lysis of K ~-but not D ~-transfected H-2 a target cells (Fig. 3, E and F) . The responses of C57B1/10 mice to these epitopes were not due to species differences of human and mouse N-Ras, since they are identical except for three COOH-terminal residues, 168, 184, and 188 (38) .
Together, the data show that C57B1/10 mice can generate CTL responses to Ras and that at least two Kb-restricted epitopes were recognized. This indicates that endogenous Ras does not lead to clonal deletion of Ras-specific T cells. One possibility is that physiologic levels of Ras expression are immunologically silent because they are insu~cient for T cell recognition. This is supported by the observation that effector CTL only recognized Ras-transfected or Vac-Ras-infected targets, but not unmanipulated cells. We are not aware of a H-2 b tumor cell line overexpressing spontaneously mutant or normal Ras, to test whether transforming levels of Ras expression would lead to CTL lysis. In vivo tumor challenge experiments with Ras transfectants will reveal whether antiRas CTL can mediate tumor protection in mice. The selective lysis of cells expressing high levels of Ras might allow the design of a CTL-based immunotherapy of certain human tumors. Recognition of transformation-associated Ras mutations would confer strict tumor spedficity to CTL. Although the recognition of a mutation-containing epitope in C57B1/10 mice is very promising, in an outbred human population the CTL-recognized epitopes will dearly depend upon the MHC haplotype. Nevertheless, the results obtained in the routine system encourage the search for Ras epitopes recognized by human CTL.
